+

WO2007036920A3 - Therapeutic use of polyanhydroglucronic acid - Google Patents

Therapeutic use of polyanhydroglucronic acid Download PDF

Info

Publication number
WO2007036920A3
WO2007036920A3 PCT/IE2006/000104 IE2006000104W WO2007036920A3 WO 2007036920 A3 WO2007036920 A3 WO 2007036920A3 IE 2006000104 W IE2006000104 W IE 2006000104W WO 2007036920 A3 WO2007036920 A3 WO 2007036920A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
paga
copolymer
salt
polyanhydroglucronic
Prior art date
Application number
PCT/IE2006/000104
Other languages
French (fr)
Other versions
WO2007036920A2 (en
Inventor
Jiri Briestensky
Ivan Santar
Vladimir Semecky
Petr Nachtigal
Anthony Richardson
Keith Real
Original Assignee
Alltracel Dev Services Ltd
Jiri Briestensky
Ivan Santar
Vladimir Semecky
Petr Nachtigal
Anthony Richardson
Keith Real
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltracel Dev Services Ltd, Jiri Briestensky, Ivan Santar, Vladimir Semecky, Petr Nachtigal, Anthony Richardson, Keith Real filed Critical Alltracel Dev Services Ltd
Publication of WO2007036920A2 publication Critical patent/WO2007036920A2/en
Publication of WO2007036920A3 publication Critical patent/WO2007036920A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a composition comprising a first component selected from a biocompatible anionic polyanhydroglucuronic acid (PAGA), a salt thereof, a copolymer thereof, and an intermolecular complex thereof, and a second component comprising an anti-lipemic agent. The present invention also provides for use of a biocompatible anionic polyanhydroglucuronic acid (PAGA), a salt thereof, a copolymer thereof or an intermolecular complex thereof, in the preparation of a medicament for the treatment of inflammation and use of a biocompatible anionic polyanhydroglucuronic acid (PAGA), a salt thereof, a copolymer thereof or an intermolecular complex thereof, in the preparation of a medicament for maintaining a patient's blood glucose concentration in a physiological range.
PCT/IE2006/000104 2005-09-28 2006-09-28 Therapeutic use of polyanhydroglucronic acid WO2007036920A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72107305P 2005-09-28 2005-09-28
US60/721,073 2005-09-28

Publications (2)

Publication Number Publication Date
WO2007036920A2 WO2007036920A2 (en) 2007-04-05
WO2007036920A3 true WO2007036920A3 (en) 2008-03-06

Family

ID=37561165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE2006/000104 WO2007036920A2 (en) 2005-09-28 2006-09-28 Therapeutic use of polyanhydroglucronic acid

Country Status (2)

Country Link
IE (1) IE20060710A1 (en)
WO (1) WO2007036920A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20120268A1 (en) * 2012-12-03 2014-06-04 Diopeite Consulting Ltd PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OBESITY

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006405A1 (en) * 1996-08-09 1998-02-19 Raisio Benecol Ltd. Stanol composition and the use thereof
WO2000004907A1 (en) * 1998-07-21 2000-02-03 Alpenstock Holdings Limited An antilipemic formulation
US20020110531A1 (en) * 2001-02-14 2002-08-15 Steven Faust Cholesterol reducing composition and method of making the same
WO2003068245A1 (en) * 2002-02-14 2003-08-21 Alpenstock Holdings Limited Use of polyanhydroglucuronic acid comprising microdispersed oxidised cellulose as immunomodulator

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006405A1 (en) * 1996-08-09 1998-02-19 Raisio Benecol Ltd. Stanol composition and the use thereof
WO2000004907A1 (en) * 1998-07-21 2000-02-03 Alpenstock Holdings Limited An antilipemic formulation
US20020110531A1 (en) * 2001-02-14 2002-08-15 Steven Faust Cholesterol reducing composition and method of making the same
WO2003068245A1 (en) * 2002-02-14 2003-08-21 Alpenstock Holdings Limited Use of polyanhydroglucuronic acid comprising microdispersed oxidised cellulose as immunomodulator

Also Published As

Publication number Publication date
WO2007036920A2 (en) 2007-04-05
IE20060710A1 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
CA2764331C (en) Anti-infective skin treatment compositions
WO2007149310A3 (en) Multiphasic biofunctional nano-components and methods for use thereof
WO2006041942A3 (en) Ocular delivery of polymeric delivery formulations
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
EP1586338A3 (en) The use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
WO2009076547A8 (en) Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
TR200201440T2 (en) Preparation of radium-223 for biomedical use
WO2006082588A3 (en) Method and device for ophthalmic administration of active pharmaceutical ingredients
WO2004003164A3 (en) Methods of organ regeneration
EP2108390A3 (en) Device for local and/or regional delivery employing liquid formulations of therapeutic agents
BR0308137A (en) Constant Release Drug Formulations Containing a Vehicle Peptide
DE602004030931D1 (en)
WO2007025142A3 (en) Gel compositions comprising a combination of an antiseptic and an anesthetic agent for treating surface areas in medical and surgical procedures
EP1637132A4 (en) External preparation for athlete´s foot treatment
WO2002060410A3 (en) Methods for sustained release local delivery of drugs for ablation of unwanted tissue
WO2006078277A3 (en) Dalbavancin compositions for treatment of bacterial infections
EP1643999B8 (en) Pyridoxamine for use in the treatment of diabetic nephropathy in type ii diabetes
EP1226822A3 (en) Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same
MXPA05008461A (en) Kit for applying drug coating to a medical device in surgeon room.
WO2008088536A8 (en) Differential drug release from a medical device
WO2007036920A3 (en) Therapeutic use of polyanhydroglucronic acid
TR200103665T2 (en) Neuro-retino-protective ophthalmological drugs
WO2003001877A3 (en) Methods for the diagnosis and treatment of cardiac tissue rejection
ES2182840T3 (en) FACTOR XIII FOR THE TREATMENT OF SKIN WOUNDS.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06796046

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载